Visfatin through STAT3 activation enhances IL-6 expression that promotes endothelial angiogenesis

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1793, Issue 11, 2009, Pages 1759-1767

  Kim, Jee Young ^a   Bae, Yun Hee ^a   Bae, Moon Kyoung ^a   Kim, Su Ryun ^a,b   Park, Hyun Joo ^a   Wee, Hee Jun ^b   Bae, Soo Kyung ^a  

^a Pusan National University   (South Korea)

^b Institute for Tumor Research   (South Korea)

Author keywords

Angiogenesis; Human endothelial cell; IL 6; STAT3; Visfatin

Indexed keywords

ALPHA TUBULIN; BETA ACTIN; BIOLOGICAL MARKER; DNA; INTERLEUKIN 6; JANUS KINASE 2; MATRIGEL; MESSENGER RNA; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; SMALL INTERFERING RNA; STAT3 PROTEIN; TYROSINE;

ANGIOGENESIS; ANIMAL CELL; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DNA BINDING; ENDOTHELIUM CELL; GENE ACTIVATION; GENE TARGETING; GENE TRANSLOCATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN PHOSPHORYLATION; RAT; RNA INTERFERENCE; SIGNAL TRANSDUCTION; UPREGULATION; VASCULAR ENDOTHELIUM; VASCULAR RING;

ANIMALS; CELLS, CULTURED; CYTOKINES; ENDOTHELIUM, VASCULAR; HUMANS; INTERLEUKIN-6; MICE; NEOVASCULARIZATION, PHYSIOLOGIC; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; RATS; RATS, SPRAGUE-DAWLEY; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR;

RATTUS;

EID: 71749115028     PISSN: 01674889     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbamcr.2009.09.006     Document Type: Article

References (43)

1. Risau W. Mechanisms of angiogenesis. Nature 386 (1997) 671-674
2. Madeddu P. Therapeutic angiogenesis and vasculogenesis for tissue regeneration. Exp. Physiol. 90 (2005) 315-326
3. Pandya N.M., Dhalla N.S., and Santani D.D. Angiogenesis-a new target for future therapy. Vascul. Pharmacol. 44 (2006) 265-274
4. Otrock Z.K., Mahfouz R.A., Makarem J.A., and Shamseddine A.I. Understanding the biology of angiogenesis: review of the most important molecular mechanisms. Blood Cells Mol. Dis. 39 (2007) 212-220
5. Ahima R.S., and Osei S.Y. Adipokines in obesity. Front. Horm. Res. 36 (2008) 182-197
6. Cao Y. Angiogenesis modulates adipogenesis and obesity. J. Clin. Invest 117 (2007) 2362-2368
7. Samal B., Sun Y., Stearns G., Xie C., Suggs S., and McNiece I. Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor. Mol. Cell. Biol. 14 (1994) 1431-1437
8. Sommer G., Garten A., Petzold S., Beck-Sickinger A.G., Bluher M., Stumvoll M., and Fasshauer M. Visfatin/PBEF/Nampt: structure, regulation and potential function of a novel adipokine. Clin. Sci. (Lond.) 115 (2008) 13-23
9. Kim S.R., Bae S.K., Choi K.S., Park S.Y., Jun H.O., Lee J.Y., Jang H.O., Yun I., Yoon K.H., Kim Y.J., Yoo M.A., Kim K.W., and Bae M.K. Visfatin promotes angiogenesis by activation of extracellular signal-regulated kinase 1/2. Biochem. Biophys. Res. Commun. 357 (2007) 150-156
10. Adya R., Tan B.K., Chen J., and Randeva H.S. Pre-B cell colony enhancing factor (PBEF)/visfatin induces secretion of MCP-1 in human endothelial cells: Role in visfatin-induced angiogenesis. Atherosclerosis 205 (2009) 113-119
11. Adya R., Tan B.K., Punn A., Chen J., and Randeva H.S. Visfatin induces human endothelial VEGF and MMP-2/9 production via MAPK and PI3K/Akt signalling pathways: novel insights into visfatin-induced angiogenesis. Cardiovasc. Res. 78 (2008) 356-365
12. Bae Y.H., Bae M.K., Kim S.R., Lee J.H., Wee H.J., and Bae S.K. Upregulation of fibroblast growth factor-2 by visfatin that promotes endothelial angiogenesis. Biochem. Biophys. Res. Commun. 379 (2009) 206-211
13. Akira S., Hirano T., Taga T., and Kishimoto T. Biology of multifunctional cytokines: IL 6 and related molecules (IL 1 and TNF). FASEB J. 4 (1990) 2860-2867
14. Hernandez-Rodriguez J., Segarra M., Vilardell C., Sanchez M., Garcia-Martinez A., Esteban M.J., Grau J.M., Urbano-Márquez A., Colomer D., Kleinman H.K., and Cid M.C. Elevated production of interleukin-6 is associated with a lower incidence of disease-related ischemic events in patients with giant-cell arteritis: angiogenic activity of interleukin-6 as a potential protective mechanism. Circulation 107 (2003) 2428-2434
15. Maruo N., Morita I., Shirao M., and Murota S. IL-6 increases endothelial permeability in vitro. Endocrinology 131 (1992) 710-714
16. Papanicolaou D.A., Wilder R.L., Manolagas S.C., and Chrousos G.P. The pathophysiologic roles of interleukin-6 in human disease. Ann. Intern. Med. 128 (1998) 127-137
17. Yudkin J.S., Kumari M., Humphries S.E., and Mohamed-Ali V. Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link?. Atherosclerosis 148 (2000) 209-214
18. Samuel J.M., Kelberman D., Smith A.J., Humphries S.E., and Woo P. Identification of a novel regulatory region in the interleukin-6 gene promoter. Cytokine 42 (2008) 256-264
19. Zhang Y.H., Lin J.X., and Vilcek J. Interleukin-6 induction by tumor necrosis factor and interleukin-1 in human fibroblasts involves activation of a nuclear factor binding to a kappa B-like sequence. Mol. Cell. Biol. 10 (1990) 3818-3823
20. Lee C., Lim H.K., Sakong J., Lee Y.S., Kim J.R., and Baek S.H. Janus kinase-signal transducer and activator of transcription mediates phosphatidic acid-induced interleukin (IL)-1beta and IL-6 production. Mol. Pharmacol. 69 (2006) 1041-1047
21. Fritzenwanger M., Meusel K., Foerster M., Kuethe F., Krack A., and Figulla H.R. Cardiotrophin-1 induces interleukin-6 synthesis in human umbilical vein endothelial cells. Cytokine 36 (2006) 101-106
22. Chen Z., and Han Z.C. STAT3: a critical transcription activator in angiogenesis. Med. Res. Rev. 28 (2008) 185-200
23. Meydan N., Grunberger T., Dadi H., Shahar M., Arpaia E., Lapidot Z., Leeder J.S., Freedman M., Cohen A., Gazit A., Levitzki A., and Roifman C.M. Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor. Nature 379 (1996) 645-648
24. Ihle J.N. STATs: signal transducers and activators of transcription. Cell 84 (1996) 331-334
25. Renehan A.G., Roberts D.L., and Dive C. Obesity and cancer: pathophysiological and biological mechanisms. Arch. Physiol. Biochem. 114 (2008) 71-83
26. Ouchi N., Kihara S., Funahashi S.T., Matsuzawa Y., and Walsh K. Obesity, adiponectin and vascular inflammatory disease. Curr. Opin. Lipidol. 14 (2003) 561-566
27. Heinrich P.C., Behrmann I., Muller-Newen G., Schaper F., and Graeve L. Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. Biochem. J. 334 (1998) 297-314
28. Hirano T., Ishihara K., and Hibi M. Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors. Oncogene 19 (2000) 2548-2556
29. Lovren F., Pan Y., Shukla P.C., Quan A., Teoh H., Szmitko P.E., Peterson M.D., Gupta M., Al-Omran M., and Verma S. Visfatin activates eNOS via Akt and MAP kinases and improves endothelial function and angiogenesis in vitro and in vivo: translational implications for atherosclerosis. Am. J. Physiol. Endocrinol. Metab. 296 (2009) E1440-E1449
30. Kim S.R., Bae Y.H., Bae S.K., Choi K.S., Yoon K.H., Koo T.H., Jang H.O., Yun I., Kim K.W., Kwon Y.G., Yoo M.A., and Bae M.K. Visfatin enhances ICAM-1 and VCAM-1 expression through ROS-dependent NF-kappaB activation in endothelial cells. Biochim. Biophys. Acta 1783 (2008) 886-895
31. Lee W.J., Wu C.S., Lin H., Lee I.T., Wu C.M., Tseng J.J., Chou M.M., and Sheu W.H. Visfatin-induced expression of inflammatory mediators in human endothelial cells through the NF-kappaB pathway. Int. J. Obes. (Lond.) 33 (2009) 465-472
32. Adya R., Tan B.K., Chen J., and Randeva H.S. Nuclear factor-kappaB induction by visfatin in human vascular endothelial cells: its role in MMP-2/9 production and activation. Diabetes Care 31 (2008) 758-760
33. Liu S.W., Qiao S.B., Yuan J.S., and Liu D.Q. Visfatin stimulates production of monocyte chemotactic protein-1 and interleukin-6 in human vein umbilical endothelial cells. Horm. Metab. Res. 41 (2009) 281-286
34. Bromberg J.F., Wrzeszczynska M.H., Devgan G., Zhao Y., Pestell R.G., Albanese C., and Darnell J.E. Stat3 as an oncogene. Cell 98 (1999) 295-303
35. Brantley E.C., and Benveniste E.N. Signal transducer and activator of transcription-3: a molecular hub for signaling pathways in gliomas. Mol. Cancer Res. 6 (2008) 675-684
36. Kunigal S., Lakka S.S., Sodadasu P.K., Estes N., and Rao J.S. Stat3-siRNA induces Fas-mediated apoptosis in vitro and in vivo in breast cancer. Int. J. Oncol. 34 (2009) 1209-1220
37. Reddy P.S., Umesh S., Thota B., Tandon A., Pandey P., Hegde A.S., Balasubramaniam A., Chandramouli B.A., Santosh V., Rao M.R., Kondaiah P., and Somasundaram K. PBEF1/NAmPRTase/Visfatin: a potential malignant astrocytoma/glioblastoma serum marker with prognostic value. Cancer Biol. Ther. 7 (2008) 663-668
38. Bae S.K., Kim S.R., Kim J.G., Kim J.Y., Koo T.H., Jang H.O., Yun I., Yoo M.A., and Bae M.K. Hypoxic induction of human visfatin gene is directly mediated by hypoxia-inducible factor-1. FEBS Lett. 580 (2006) 4105-4113
39. Stephenson G.D., and Rose D.P. Breast cancer and obesity: an update. Nutr. Cancer 45 (2003) 1-16
40. Zhang G.J., and Adachi I. Serum interleukin-6 levels correlate to tumor progression and prognosis in metastatic breast carcinoma. Anticancer Res. 19 (1999) 1427-1432
41. Luk T., Malam Z., and Marshall J.C. Pre-B cell colony-enhancing factor (PBEF)/visfatin: a novel mediator of innate immunity. J. Leukoc. Biol. 83 (2008) 804-816
42. Marin V., Montero-Julian F.A., Gres S., Boulay V., Bongrand P., Farnarier C., and Kaplanski G. The IL-6-soluble IL-6Ralpha autocrine loop of endothelial activation as an intermediate between acute and chronic inflammation: an experimental model involving thrombin. J. Immunol. 167 (2001) 3435-3442
43. Li Y., Zhang Y., Dorweiler B., Cui D., Wang T., Woo C.W., Brunkan C.S., Wolberger C., Imai S., and Tabas I. Extracellular Nampt promotes macrophage survival via a nonenzymatic interleukin-6/STAT3 signaling mechanism. J. Biol. Chem. 283 (2008) 34833-34843